RECURRENT CANCER

This study tests a personalized vaccine made from a patient's own tumor mutations. It aims to train the immune system to fight advanced or high-risk solid tumors. Ten adults will receive the vaccine along with immune-boosting drugs. Researchers will check safety and whether the c…

This study tests a drug called cabozantinib in 20 adults whose liver cancer came back after a liver transplant. The goal is to see if the drug can control the cancer and slow its growth. Participants take the drug until it stops working or side effects become too severe.

This study tests new cancer drugs that are chosen based on the unique genetic makeup of each child's tumor. It is for children, teens, and young adults with advanced solid tumors, brain tumors, or lymphoma that have not responded to standard treatments. The goal is to find the ri…

This study tests a new radiation technique for people with cervical cancer or pelvic cancer that has come back. It is for those who cannot get standard brachytherapy because of unusual anatomy or large tumors. The goal is to see if this method can control the cancer in the treate…

This early-phase trial tests an experimental drug called IMA402 in about 145 adults with advanced solid tumors that have returned or not responded to standard treatments. IMA402 is a bispecific T-cell engager designed to direct the immune system to attack cancer cells carrying a …

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. Some participants will also receive an immunotherapy drug …

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…